Stephen Harbin, MD
Family Medicine · Decatur, ALNPI 1396813002
Payments from drug & device makers
Across 191 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$748
- Pfizer$298
- Lilly USA, LLC$272
- AbbVie$266
- Bayer$259
- Amarin Pharma, Inc.$214
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,27397%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 40 | $748 |
| Pfizer | 19 | $298 |
| Lilly USA, LLC | 17 | $272 |
| AbbVie(2 entities) | 18 | $266 |
| Bayer | 14 | $259 |
| Amarin Pharma, Inc. | 11 | $214 |
| Merck | 11 | $173 |
| Astellas Pharma US Inc | 4 | $144 |
| GSK | 6 | $114 |
| Eisai Inc. | 4 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $73 |
| Esperion Therapeutics, Inc. | 4 | $72 |
| Exact Sciences | 4 | $67 |
| Novartis | 4 | $63 |
| Sanofi Pasteur Inc. | 1 | $53 |
| Boehringer Ingelheim | 3 | $52 |
| Kowa Pharmaceuticals America, Inc. | 4 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| AstraZeneca | 3 | $40 |
| Amgen | 2 | $34 |
| Johnson & Johnson | 2 | $30 |
| Genentech USA, Inc. | 2 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Ironwood Pharmaceuticals, Inc | 1 | $14 |
How this compares
$3,373 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 178 | $168,244 |
| MounjaroTirzepatide | 103 | $121,366 |
| OzempicSemaglutide | 62 | $112,366 |
| FarxigaDapagliflozin Propanediol | 78 | $83,772 |
| JanuviaSitagliptin Phosphate | 68 | $66,859 |
| JardianceEmpagliflozin | 53 | $59,320 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 63 | $50,317 |
| XareltoRivaroxaban | 31 | $38,140 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 33 | $34,378 |
| TrulicityDulaglutide | 25 | $33,515 |
| EntrestoSacubitril/Valsartan | 19 | $24,818 |
| LinzessLinaclotide | 33 | $22,573 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $17,580 |
| InvokametCanagliflozin/Metformin Hcl | 16 | $17,219 |
| Xigduo XrDapaglifloz Propaned/Metformin | 21 | $16,927 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $298 | $168,244178 claims |
| Lilly USA, LLCMounjaro, Trulicity | $272 | $154,881128 claims |
| MerckJanuvia, Janumet Xr, Janumet | $173 | $134,756146 claims |
| Novo NordiskOzempic | $748 | $112,36662 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Synjardy | $52 | $105,67098 claims |
| AstraZenecaFarxiga, Symbicort | $40 | $89,24194 claims |
| Johnson & JohnsonXarelto, Invokamet | $30 | $55,35947 claims |
| NovartisEntresto | $63 | $24,81819 claims |
| AbbVieLinzess | $266 | $22,57333 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $114 | $19,75822 claims |
| Astellas Pharma US IncMyrbetriq | $144 | $16,75832 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Decatur
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
- Timothy HowardHuntsville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.